The new, versatile platform offers two configurations, a combined console (VCS) as well as a standalone cataract system (CS). This platform is designed to deliver superior efficiency for vitreoretinal ...

"The EVSS represents a new paradigm in peripheral interventions," said Christopher Haig, Co-Founder and CEO of Efemoral Medical. "It's easy to deploy, has high radial strength, can be made in longer ...

Collaboration will deliver innovative AI-powered pathology tools and quality control enhancements to accelerate clinical trials and biomarker discovery. Precision for Medicine, a leading provider of ...

The new, versatile platform offers two configurations, a combined console (VCS) as well as a standalone cataract system (CS). This platform is designed to deliver superior efficiency for vitreoretinal ...

Legare Boyle, RN, of Greenville, South Carolina rewarded for compassionate patient care and heroic community service during Hurricane Helene recovery .

VERAXA Biotech’s majority shareholders are Xlife Sciences AG (SIX: XLS), a Swiss-based publicly listed life science incubator fund, the European Molecular Biology Laboratory ("EMBL"), and its ...

Collaboration will deliver innovative AI-powered pathology tools and quality control enhancements to accelerate clinical trials and biomarker discovery. Continue ReadingPrecision for Medicine and ...

Continue ReadingSecond Phase of ADVANTAGE AF study of FARAPULSE ™ Pulsed Field Ablation System Meets Primary Safety and Efficacy Endpoints ...

The Series B-1 warrants will have an exercise price of $0.85 per share, will be immediately exercisable and will expire 5 years from issuance. The Series B-2 warrants will have an exercise price of $0 ...

CorWave, a medical device company dedicated to the fight against heart failure, announces new preclinical results of its implantable heart pump. CorWave’s in vivo studies demonstrated the pump’s ...

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the FARAPULSE™ ...

The Decipher Prostate test, already widely used for patients with localized disease, is now the only gene expression test available and covered by Medicare to inform treatment decisions for patients ...